Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Novartis Pharmaceuticals11 sites in 1 country297 target enrollmentJuly 30, 2021

ConditionsSickle Cell Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Sickle Cell Disease
Sponsor: Novartis Pharmaceuticals
Enrollment: 297
Locations: 11
Primary Endpoint: Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

Registry

clinicaltrials.gov

Start Date

July 30, 2021

End Date

April 18, 2022

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Novartis Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab

Time Frame: Up to 12 months

Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab

Time Frame: Up to 12 months

Secondary Outcomes

Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab(Up to 24 months)
Number of sickle cell disease (SCD)-related hospitalizations(Up to 24 months)
Number of patients who discontinued treatment with crizanlizumab(Up to 24 months)
Reasons for early discontinuation of crizanlizumab treatment(Up to 24 months)
Number of SCD-related emergency department (ED) visits(Up to 24 months)